Pharvaris N.V.

Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, oral bradykinin B2 receptor antagonists. The company's core mission is to address significant unmet medical needs and improve the standard of care for individuals living with bradykinin-mediated conditions, primarily hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Founded in 2015, Pharvaris maintains its registered office in Leiden, the Netherlands, with corporate headquarters also located in Zug, Switzerland.

The company's lead product candidate is deucrictibant (also known as PHVS416, PHVS719, PHA121, or PHA-022121), a small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing two distinct oral formulations of deucrictibant: an immediate-release (IR) capsule for the on-demand treatment of acute HAE attacks and an extended-release (XR) tablet for the prophylactic (preventative) treatment of HAE attacks. Both formulations are currently in pivotal Phase 3 clinical studies, with CHAPTER-3 evaluating prophylaxis and RAPIDe-3 assessing on-demand treatment.

Recent notable developments include the presentation of evidence supporting the combined use of deucrictibant IR and XR at the CIIC Spring 2026 Conference in April 2026. The company also reported its fourth quarter and full year 2025 financial results in April 2026, providing a business update. Topline data for the CHAPTER-3 study (HAE prophylaxis) is anticipated in the third quarter of 2026, and the New Drug Application (NDA) submission for deucrictibant IR (on-demand HAE treatment) is on track for the first half of 2026. Berndt Modig serves as the CEO and co-founder, leading the company's efforts to provide convenient oral alternatives to existing injectable therapies.